{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:06:00Z","timestamp":1792800360751,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSD, Belgium"},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1242021N"],"award-info":[{"award-number":["1242021N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research council of the Vrije Universiteit Brussel","award":["OZR3863BOF"],"award-info":[{"award-number":["OZR3863BOF"]}],"id":[{"id":"https:\/\/ror.org\/006e5kg04","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Internal Funds KU Leuven","award":["3M190682"],"award-info":[{"award-number":["3M190682"]}],"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since 2014, Belgium\u2019s Superior Health Council has recommended pneumococcal vaccination for adults aged 19\u201385\u00a0years at increased risk for pneumococcal diseases with a specific vaccine administration sequence and timing. Currently, Belgium has no publicly funded adult pneumococcal vaccination program. This study investigated the seasonal pneumococcal vaccination trends, evolution of vaccination coverage and adherence to the 2014 recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>INTEGO is a general practice morbidity registry in Flanders (Belgium) that represents 102 general practice centres and comprised over 300.000 patients in 2021. A repeated cross-sectional study was performed for the period between 2017 and 2021. Using adjusted odds ratios computed via multiple logistic regression, the association between an individual\u2019s characteristics (gender, age, comorbidities, influenza vaccination status and socioeconomic status) and schedule-adherent pneumococcal vaccination status was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pneumococcal vaccination coincided with seasonal flu vaccination. The vaccination coverage in the population at risk decreased from 21% in 2017 to 18.2% in 2018 and then started to increase to 23.6% in 2021. Coverage in 2021 was highest for high-risk adults (33.8%) followed by 50- to 85-year-olds with comorbidities (25.5%) and healthy 65- to 85-year-olds (18.7%). In 2021, 56.3% of the high-risk adults, 74.6% of the 50+\u2009with comorbidities persons, and 74% of the 65+\u2009healthy persons had an adherent vaccination schedule. Persons with a lower socioeconomic status had an adjusted odds ratio of 0.92 (95% Confidence Interval (CI) 0.87\u20130.97) for primary vaccination, 0.67 (95% CI 0.60\u20130.75) for adherence to the recommended second vaccination if the 13-valent pneumococcal conjugate vaccine was administered first and 0.86 (95% CI 0.76\u20130.97) if the 23-valent pneumococcal polysaccharide vaccine was administered first.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pneumococcal vaccine coverage is slowly increasing in Flanders, displaying seasonal peaks in sync with influenza vaccination campaigns. However, with less than one-fourth of the target population vaccinated, less than 60% high-risk and approximately 74% of 50\u2009+\u2009with comorbidities and 65+\u2009healthy persons with an adherent schedule, there is still much room for improvement. Furthermore, adults with poor socioeconomic status had lower odds of primary vaccination and schedule adherence, demonstrating the need for a publicly funded program in Belgium to ensure equitable access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-023-15939-7","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T06:02:59Z","timestamp":1686117779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry"],"prefix":"10.1186","volume":"23","author":[{"given":"Arne","family":"Janssens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Vaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Abels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Cr\u00e8vecoeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Mamouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Merckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Libin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs","family":"Van Pottelbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Neyens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"11","key":"15939_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","volume":"68","author":"A Torres","year":"2013","unstructured":"Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057\u201365. https:\/\/doi.org\/10.1136\/thoraxjnl-2013-204282.","journal-title":"Thorax"},{"issue":"3","key":"15939_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10096-012-1778-4","volume":"32","author":"MH Rozenbaum","year":"2013","unstructured":"Rozenbaum MH, Pechlivanoglou P, van der Werf TS, et al. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32(3):305\u201316. https:\/\/doi.org\/10.1007\/s10096-012-1778-4.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"15939_CR3","unstructured":"Business Wire. European Commission Approves Merck\u2019s VAXNEUVANCETM (Pneumococcal 15-Valent Conjugate Vaccine) for Individuals 18 Years of Age and Older. 2021. Available from: https:\/\/www.businesswire.com\/news\/home\/20211215005345\/en\/ [Last accessed: 6\/6\/2022]."},{"key":"15939_CR4","unstructured":"Business Wire. European Medicines Agency Approves Pfizer\u2019s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults. 2022. Available from: https:\/\/www.businesswire.com\/news\/home\/20220215005838\/en\/ [Last accessed: 6\/6\/2022]."},{"issue":"10","key":"15939_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12325-014-0157-1","volume":"31","author":"P Castiglia","year":"2014","unstructured":"Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014;31(10):1011\u201344. https:\/\/doi.org\/10.1007\/s12325-014-0157-1.","journal-title":"Adv Ther"},{"issue":"4","key":"15939_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10096-019-03485-3","volume":"38","author":"C Bonnave","year":"2019","unstructured":"Bonnave C, Mertens D, Peetermans W, et al. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. Eur J Clin Microbiol Infect Dis. 2019;38(4):785\u201391. https:\/\/doi.org\/10.1007\/s10096-019-03485-3.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"15939_CR7","unstructured":"European Centre for Disease Prevention and Control (ECDC). Pneumococcal Disease: Recommended Vaccinations. 2022. Available from: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1 [Last accessed: 6\/6\/2022]."},{"key":"15939_CR8","unstructured":"Blommaert A, Hanquet G, Willem L, Theeten H, Thiry N, Bilcke J, et al. Use of pneumococcal vaccines in\u00a0the elderly: an economic evaluation \u2013 synthesis. Health Technology Assessment (HTA) Brussels: Belgian Health Care\u00a0Knowledge Centre (KCE); 2016. KCE Reports 274Cs. D\/2016\/10.273\/78."},{"key":"15939_CR9","unstructured":"Hoge Gezondheidsraad. Vaccinatie tegen pneumokokken (volwassenen). Brussel: HGR; 2014. Advies nr. 9210."},{"key":"15939_CR10","unstructured":"Hoge Gezondheidsraad. Vaccinatie tegen pneumokokken (volwassenen). Brussel: HGR; 2020. Advies nr. 9562."},{"key":"15939_CR11","unstructured":"Hoge Gezondheidsraad. Vaccinatie tegen pneumokokken (volwassenen). Brussel: HGR; 2022. Advies nr. 9674."},{"key":"15939_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jclinepi.2021.12.008","volume":"143","author":"P Mamouris","year":"2022","unstructured":"Mamouris P, Henrard S, Molenberghs G, et al. Pneumococcal vaccination prevented severe LRTIs in adults: a causal inference framework applied in registry data. J Clin Epidemiol. 2022;143:118\u201327. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.12.008.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"15939_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14760584.2021.1898377","volume":"20","author":"A Deb","year":"2021","unstructured":"Deb A, Mohanty S, Ou W, et al. Pneumococcal vaccination coverage among adults aged 19 to 64 years with immuno-compromising conditions, cerebrospinal fluid (CSF) leaks, or cochlear implants in the US. Expert Rev Vaccines. 2021;20(3):331\u201345. https:\/\/doi.org\/10.1080\/14760584.2021.1898377.","journal-title":"Expert Rev Vaccines"},{"key":"15939_CR14","unstructured":"KOVAG. Vaccineren tegen pneumokokken: we zijn er nog niet! 2018. Available from: https:\/\/www.kovag.be\/tarifering_artsen\/uploads\/documentenbank\/b7b8db294e42c7f249628f3fca14c087.pdf [Last accessed: 9\/13\/2022]."},{"issue":"5","key":"15939_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/17843286.2020.1735113","volume":"76","author":"T De Burghgraeve","year":"2021","unstructured":"De Burghgraeve T, Henrard S, Verboven B, et al. The incidence of lower respiratory tract infections and pneumococcal vaccination status in adults in flemish primary care. Acta Clin Belg. 2021;76(5):335\u201345. https:\/\/doi.org\/10.1080\/17843286.2020.1735113.","journal-title":"Acta Clin Belg"},{"issue":"3","key":"15939_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/healthcare4030036","volume":"4","author":"F Fischer","year":"2016","unstructured":"Fischer F, Lange K, Klose K, et al. Barriers and Strategies in Guideline Implementation\u2014A Scoping Review. Healthcare. 2016;4(3):36. https:\/\/doi.org\/10.3390\/healthcare4030036.","journal-title":"Healthcare"},{"issue":"1","key":"15939_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1472-6947-14-48","volume":"14","author":"C Truyers","year":"2014","unstructured":"Truyers C, Goderis G, Dewitte H, et al. The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project. BMC Med Inform Decis Mak. 2014;14(1):48. https:\/\/doi.org\/10.1186\/1472-6947-14-48.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"4","key":"15939_CR18","doi-asserted-by":"publisher","first-page":"e11428","DOI":"10.2196\/11428","volume":"6","author":"N Delvaux","year":"2018","unstructured":"Delvaux N, Aertgeerts B, van Bussel JC, et al. Health data for research through a nationwide privacy-proof system in belgium: design and implementation. JMIR Med Inform. 2018;6(4):e11428. https:\/\/doi.org\/10.2196\/11428.","journal-title":"JMIR Med Inform"},{"key":"15939_CR19","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020. https:\/\/www.R-project.org\/."},{"key":"15939_CR20","unstructured":"IQVIA. 2020 ACTS annual report: statistical quality assurance, applied to IQVIA\u2019s information offerings. 2021. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/publications\/2020-acts-annual-report.pdf. Accessed 6 Jan 2023."},{"key":"15939_CR21","unstructured":"IQVIA. 2021 ACTS annual report: statistical quality assurance, applied to IQVIA\u2019s information offerings. 2022. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/publications\/2021-acts-annual-report.pdf. Accessed 6 Jan 2023."},{"key":"15939_CR22","unstructured":"Superior Health Council. Booster vaccination against COVID-19 for the general population. Brussels: SHC; 2021. Report\u00a09683."},{"key":"15939_CR23","unstructured":"RIVM. Pneumokokkenprik Voor Volwassenen - Vaccinatiegraad. 2022. Available from: https:\/\/www.rivm.nl\/pneumokokken\/pneumokokkenprik\/vaccinatiegraad [Last accessed: 6\/2\/2022]."},{"key":"15939_CR24","unstructured":"Valentiner-Branth P. No 14\/16 - 2020: Pneumococcal Vaccination Programme for Persons Aged 65 Years or More and for Risk Groups. Statens Serum Institut. 2020. Available from: https:\/\/en.ssi.dk\/news\/epi-news\/2020\/no-14---2020 [Last accessed: 6\/6\/2022]."},{"key":"15939_CR25","unstructured":"Valentiner-Branth P. No 23 - 2020: Everyone above 65 Years of Age Will Be Offered Pneumococcal Vaccination. Statens Serum Institut. 2020. Available from: https:\/\/en.ssi.dk\/news\/epi-news\/2020\/no-23---2020 [Last accessed: 6\/6\/2022]."},{"key":"15939_CR26","unstructured":"Statens Serum Institut. No 44\/45 - 2020: Update on Influenza and Pneumococcal Vaccination. 2020. Available from: https:\/\/en.ssi.dk\/news\/epi-news\/2020\/no-44-45---2020 [Last accessed: 6\/6\/2022]."},{"key":"15939_CR27","volume-title":"Impfquoten bei Erwachsenen in Deutschland, STIKO: Best\u00e4tigung der Pneumokokken-Impfempfehlung. Epidemiologisches Bulletin","author":"Standing Vaccination Committee (STIKO) at the Robert Koch Institute","year":"2020","unstructured":"Standing Vaccination Committee (STIKO) at the Robert Koch Institute. Impfquoten bei Erwachsenen in Deutschland, STIKO: Best\u00e4tigung der Pneumokokken-Impfempfehlung. Epidemiologisches Bulletin. Berlin: Robert Koch-Institut; 2020."},{"issue":"9","key":"15939_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11298-020-8043-4","volume":"17","author":"M Wallenfels","year":"2020","unstructured":"Wallenfels M. Pneumokokken-Vakzine: Corona f\u00fchrt zu hoher Impfbereitschaft. CME Berl Ger. 2020;17(9):29. https:\/\/doi.org\/10.1007\/s11298-020-8043-4.","journal-title":"CME Berl Ger"},{"issue":"3","key":"15939_CR29","doi-asserted-by":"publisher","first-page":"e0265433","DOI":"10.1371\/journal.pone.0265433","volume":"17","author":"R Sprenger","year":"2022","unstructured":"Sprenger R, H\u00e4ckl D, Kossack N, et al. Pneumococcal vaccination rates in immunocompromised patients in Germany: A retrospective cohort study to assess sequential vaccination rates and changes over time. PLOS ONE. 2022;17(3):e0265433. https:\/\/doi.org\/10.1371\/journal.pone.0265433.","journal-title":"PLOS ONE"},{"key":"15939_CR30","unstructured":"Heins M, Hooiveld M, Korevaar J. Monitor Vaccinatiegraad Nationaal Programma Pneumokokkenvaccinatie Volwassenen\u00a0(NPPV) 2020. Utrecht: NIVEL; 2021."},{"issue":"7","key":"15939_CR31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1525-1497.2005.0118.x","volume":"20","author":"LS Miller","year":"2005","unstructured":"Miller LS, Kourbatova EV, Goodman S, et al. Brief report: risk factors for pneumococcal vaccine refusal in adults: a casecontrol study. J Gen Intern Med. 2005;20(7):650\u20132. https:\/\/doi.org\/10.1111\/j.1525-1497.2005.0118.x.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"15939_CR32","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1186\/s12889-018-6080-7","volume":"18","author":"A Sakamoto","year":"2018","unstructured":"Sakamoto A, Chanyasanha C, Sujirarat D, et al. Factors associated with pneumococcal vaccination in elderly people: a cross-sectional study among elderly club members in Miyakonojo City, Japan. BMC Public Health. 2018;18(1):1172. https:\/\/doi.org\/10.1186\/s12889-018-6080-7.","journal-title":"BMC Public Health"},{"issue":"2","key":"15939_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ypmed.2008.11.001","volume":"48","author":"WS Pearson","year":"2009","unstructured":"Pearson WS, Dube SR, Ford ES, et al. Influenza and pneumococcal vaccination rates among smokers: data from the 2006 Behavioral Risk Factor Surveillance System. Prev Med. 2009;48(2):180\u20133. https:\/\/doi.org\/10.1016\/j.ypmed.2008.11.001.","journal-title":"Prev Med"},{"issue":"9","key":"15939_CR34","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/ntr\/ntab039","volume":"23","author":"SE Jackson","year":"2021","unstructured":"Jackson SE, Paul E, Brown J, et al. Negative Vaccine Attitudes and Intentions to Vaccinate Against Covid-19 in Relation to Smoking Status: A Population Survey of UK Adults. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2021;23(9):1623\u20138. https:\/\/doi.org\/10.1093\/ntr\/ntab039.","journal-title":"Nicotine Tob Res Off J Soc Res Nicotine Tob"},{"issue":"6","key":"15939_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.5588\/ijtld.14.0480","volume":"19","author":"LV Carre\u00f1o-Ib\u00e1\u00f1ez","year":"2015","unstructured":"Carre\u00f1o-Ib\u00e1\u00f1ez LV, Esteban-Vasallo MD, Dom\u00ednguez-Berj\u00f3n MF, et al. Coverage of and factors associated with pneumococcal vaccination in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2015;19(6):735\u201341. https:\/\/doi.org\/10.5588\/ijtld.14.0480.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"15939_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4274\/balkanmedj.2016.1028","volume":"34","author":"\u00dc Aka Akt\u00fcrk","year":"2017","unstructured":"Aka Akt\u00fcrk \u00dc, G\u00f6rek Dilekta\u015fl\u0131 A, \u015eeng\u00fcl A, et al. Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease. Balk Med J. 2017;34(3):206\u201311. https:\/\/doi.org\/10.4274\/balkanmedj.2016.1028.","journal-title":"Balk Med J"},{"issue":"4","key":"15939_CR37","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.4161\/hv.27697","volume":"10","author":"SA Baig","year":"2014","unstructured":"Baig SA, Hassan M, Ahmed SM, et al. A cross-sectional study to investigate pneumococcal vaccination in the elderly in a low income county: Patient knowledge, awareness, and attitudes of vaccination and prevalence rates by socioeconomic status. Hum Vaccines Immunother. 2014;10(4):1024. https:\/\/doi.org\/10.4161\/hv.27697.","journal-title":"Hum Vaccines Immunother"},{"issue":"4","key":"15939_CR38","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/21645515.2018.1564434","volume":"15","author":"JM McLaughlin","year":"2019","unstructured":"McLaughlin JM, Swerdlow DL, Khan F, et al. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. Hum Vaccines Immunother. 2019;15(4):841. https:\/\/doi.org\/10.1080\/21645515.2018.1564434.","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"15939_CR39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/21645515.2018.1509644","volume":"15","author":"O Tsachouridou","year":"2019","unstructured":"Tsachouridou O, Georgiou A, Naoum S, et al. Factors associated with poor adherence to vaccination against hepatitis viruses, streptococcus pneumoniae and seasonal influenza in HIV-infected adults. Hum Vaccines Immunother. 2019;15(2):295\u2013304. https:\/\/doi.org\/10.1080\/21645515.2018.1509644.","journal-title":"Hum Vaccines Immunother"},{"issue":"8","key":"15939_CR40","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1586\/erv.11.99","volume":"10","author":"DS Fedson","year":"2011","unstructured":"Fedson DS, Nicolas-Spony L, Klemets P, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 2011;10(8):1143\u201367. https:\/\/doi.org\/10.1586\/erv.11.99.","journal-title":"Expert Rev Vaccines"},{"issue":"29","key":"15939_CR41","doi-asserted-by":"publisher","first-page":"1800446","DOI":"10.2807\/1560-7917.ES.2019.24.29.1800446","volume":"24","author":"A Vila-C\u00f3rcoles","year":"2019","unstructured":"Vila-C\u00f3rcoles A, Ochoa-Gondar O, de Diego C, et al. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. Eurosurveillance. 2019;24(29):1800446. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.29.1800446.","journal-title":"Eurosurveillance"},{"key":"15939_CR42","unstructured":"UK Health Security Agency. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2020 to March 2021. 2021. Available from: https:\/\/www.gov.uk\/government\/publications\/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates. Accessed 6 Mar 2022."},{"key":"15939_CR43","unstructured":"MesVaccins.net. PREVENAR 13. 2021. Available from: http:\/\/www.mesvaccins.net\/web\/vaccines\/123-prevenar-13 [Last accessed: 6\/9\/2022]."},{"key":"15939_CR44","unstructured":"MesVaccins.net. PNEUMOVAX. 2022. Available from: http:\/\/www.mesvaccins.net\/web\/vaccines\/336-pneumovax [Last accessed: 6\/9\/2022]."},{"key":"15939_CR45","unstructured":"Public Health Agency of Sweden. Pneumokockvaccination som ett s\u00e4rskilt vaccinationsprogram f\u00f6r personer 75 \u00e5r och \u00e4ldre. 2021. Available from: https:\/\/www.folkhalsomyndigheten.se\/publicerat-material\/publikationsarkiv\/p\/pneumokockvaccination-som-ett-sarskilt-vaccinationsprogram-for-personer-75-ar-och-aldre\/ [Last accessed: 6\/3\/2022]."},{"key":"15939_CR46","unstructured":"Public Health Agency of Sweden. Vaccination Programmes. 2022. Available from: https:\/\/www.folkhalsomyndigheten.se\/the-public-health-agency-of-sweden\/communicable-disease-control\/vaccinations\/vaccination-programmes\/ [Last accessed: 6\/3\/2022]."},{"key":"15939_CR47","doi-asserted-by":"publisher","first-page":"CD000422","DOI":"10.1002\/14651858.CD000422.pub3","volume":"1","author":"S Moberley","year":"2013","unstructured":"Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422. https:\/\/doi.org\/10.1002\/14651858.CD000422.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"15939_CR48","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.lanepe.2021.100126","volume":"7","author":"S Perniciaro","year":"2021","unstructured":"Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study. Lancet Reg Health \u2013. 2021;7:100126. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100126.","journal-title":"Lancet Reg Health \u2013 Eur"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-15939-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T06:04:33Z","timestamp":1686117873000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-15939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["15939"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-15939-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"13 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Belgian Privacy Commission (no. SCSZG\/13\/079), \u201cInformatieveiligheidscomit\u00e9, Kamer sociale zekerheid en gezondheid\u201d, and the ethical review board of the Medical School of the KU Leuven (no. ML 1723), \u201cEthische Commissie Onderzoek UZ\/KU Leuven\u201d (Herestraat 49, 3000 Leuven), waived the requirement of informed consent and approved the INTEGO protocol [\n                      \n                      ,\n                      \n                      ].INTEGO uses an opt-out procedure for patients who do not wish their data to be included. All patients are informed about INTEGO procedures via a poster in the waiting room of the participating general practice centres and can inform via their general practitioner if they do not want their data to be exported to the INTEGO registry. All this was approved by the aforementioned Belgian Privacy Commission and ethical review board of the Medical School of the KU Leuven.Participant data were pseudonymized before use. All protocols are carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Coauthors C.A. and B.M. are employees of MSD, Belgium. All other authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1104"}}